The Pharma Data

DECEMBER 23, 2020

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. It is approved in Argentina as the world’s first therapy for severe Chronic Fatigue Syndrome and is the only late-stage drug in the U.S. Ampligen is AIM’s TLR3 agonist immune-system modulator. development pipeline for ME/CFS.

Clinical Trials 52

Clinical Trials Trials Virus International 52

The Pharma Data

FEBRUARY 12, 2022

The approval extends the current indication in China as add-on therapy in adults and children aged five years and older with active systemic lupus erythematosus (SLE). The BLISS-LN phase III trial is the largest and longest trial conducted in active LN, involving 448 adult patients. About the BLISS-LN trial. About lupus.

Production 52

Production Therapies Trials Disease 52

NIH Director's Blog: Drug Development

MAY 21, 2020

Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19. In the U.S.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

JULY 22, 2021

Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). Biogen Inc.

Disease 52

Disease Research Clinical Trials FDA 52

The Pharma Data

MAY 5, 2021

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).

Therapies 52

Therapies Disease Treatment International 52

Drug Target Review

NOVEMBER 30, 2023

Then I was approached to co-found AC Immune in 2003. Food and Drug Administration for our Alzheimer’s vaccine candidate, ACI-24.060. We are the only company in the world including this population in any Alzheimer’s drug trial, and we are very proud of this! COVID-19 has shown the revolutionary impact of vaccines.

Disease 95

Disease Laboratories Therapies Treatment 95

The Pharma Data

FEBRUARY 25, 2021

FDA ACCEPTS FOR PRIORITY REVIEW PFIZER’S APPLICATION FOR TICOVAC (TICK-BORNE ENCEPHALITIS VACCINE). If approved, the vaccine may help reduce the risk of TBE for people traveling to endemic areas, potentially including military personnel serving in these locations. 1,2 If approved, TicoVac would be the first vaccine in the U.S.

FDA 52

FDA Vaccine Virus Clinical Trials 52